Trident Lifeline
300.00
-1.00(-0.33%)
Market Cap₹350.93 Cr
PE Ratio21.24
IndustryHealthcare
Company Performance:
1D-0.33%
1M-5.57%
6M+10.05%
1Y+7.10%
5Y+177.39%
View Company Insightsright
More news about Trident Lifeline
16Apr 25
Trident Lifeline Approves Issue of Convertible Warrants, Plans to Raise Up to ₹26.57 Crore
Trident Lifeline's Board of Directors has approved the issuance of 9,99,000 fully convertible warrants at ₹266 each, potentially raising ₹26.57 crore. The warrants are convertible into equity shares within 18 months of allotment. The company also plans to increase its Authorized Share Capital from ₹12 crore to ₹15 crore, subject to shareholder approval. An EGM is scheduled for May 9, 2025, to seek necessary approvals.
09Apr 25
Trident Lifeline to Consider Fund Raising and Share Capital Increase in Upcoming Board Meeting
Trident Lifeline Limited has scheduled a board meeting for April 16, 2025, to discuss and potentially approve significant financial initiatives. The agenda includes increasing authorized share capital, issuing equity shares or convertible warrants on a preferential basis, and setting up an Extra-Ordinary General Meeting (EGM) for shareholder approval. The company has closed the trading window for insiders from April 1, 2025, until 48 hours after the declaration of audited financial results for the quarter and year ended March 31, 2025.
Trident Lifeline
300.00
-1.00
(-0.33%)
1 Year Returns:+7.10%
Industry Peers
Sun Pharmaceutical
1,807.20
(+1.22%)
Divis Laboratories
6,430.00
(+2.15%)
Torrent Pharmaceuticals
3,799.00
(+0.12%)
Cipla
1,512.30
(+1.44%)
Dr Reddys Laboratories
1,273.50
(+1.81%)
Lupin
2,081.80
(+1.28%)
Zydus Life Science
922.55
(-0.11%)
Mankind Pharma
2,166.80
(+0.83%)
Aurobindo Pharma
1,172.20
(-0.03%)
Alkem Laboratories
5,626.00
(+0.49%)